Diphtheria News and Research

RSS
Diphtheria is a disease caused by a bacterium, Corynebacterium diphtheriae, that usually affects the tonsils, throat, nose and/or skin. It is passed from person to person by droplet transmission, usually by breathing in diphtheria bacteria after an infected person has coughed or sneezed. Although diphtheria disease is rare in the U.S., it appears that C diphtheriae continues to circulate in areas of the country with previously endemic diphtheria. Diphtheria also occurs in many other parts of the world.
Tikcro reports net loss of $30,000 for first quarter 2011

Tikcro reports net loss of $30,000 for first quarter 2011

GAVI welcomes lower pentavalent vaccine price

GAVI welcomes lower pentavalent vaccine price

Department of Health urges caregivers, parents to update students' immunizations

Department of Health urges caregivers, parents to update students' immunizations

Afghan Acting Health Minister says country wants to boost immunization access

Afghan Acting Health Minister says country wants to boost immunization access

Haiti presents plan to immunize 90 percent of newborns

Haiti presents plan to immunize 90 percent of newborns

NBA Cares, SAHM and Tulsa Shock guard partner for teen vaccine awareness campaign

NBA Cares, SAHM and Tulsa Shock guard partner for teen vaccine awareness campaign

Rwanda, QIAGEN and Merck launch comprehensive national cervical cancer prevention program

Rwanda, QIAGEN and Merck launch comprehensive national cervical cancer prevention program

Ahead of Immunization Week, WHO calls for countries to come together to control measles outbreak in Europe

Ahead of Immunization Week, WHO calls for countries to come together to control measles outbreak in Europe

FDA approves Sanofi Pasteur's meningococcal vaccine

FDA approves Sanofi Pasteur's meningococcal vaccine

Merck and Sanofi Pasteur commence Phase III trial of pediatric hexavalent combination vaccine

Merck and Sanofi Pasteur commence Phase III trial of pediatric hexavalent combination vaccine

Nuron Biotech announces acquisition of Wyeth's HibTITER vaccine assets

Nuron Biotech announces acquisition of Wyeth's HibTITER vaccine assets

Lancet Infectious Diseases examines how resource gaps are creating barriers to reduce child mortality

Lancet Infectious Diseases examines how resource gaps are creating barriers to reduce child mortality

Symposium examines Bruesewitz vs. Wyeth Supreme Court case

Symposium examines Bruesewitz vs. Wyeth Supreme Court case

New nanoparticle can help develop vaccines against HIV, malaria

New nanoparticle can help develop vaccines against HIV, malaria

CVS condemns Supreme Court's decision to preempt all vaccine design defect lawsuits

CVS condemns Supreme Court's decision to preempt all vaccine design defect lawsuits

New study shows economic burden of dengue in Western Hemisphere is $2.1 billion per year

New study shows economic burden of dengue in Western Hemisphere is $2.1 billion per year

Merck announces publication of GARDASIL pivotal Phase III study data in NEJM

Merck announces publication of GARDASIL pivotal Phase III study data in NEJM

Bill Gates, crown prince of Abu Dhabi announce $100m pledge for vaccines for Afghan, Pakistani children

Bill Gates, crown prince of Abu Dhabi announce $100m pledge for vaccines for Afghan, Pakistani children

Lancet series examines health issues facing populations in Southeast Asia

Lancet series examines health issues facing populations in Southeast Asia

UMMS begins MBL-HCV1 Phase 2 trial to prevent hepatitis C virus infection in liver transplant patients

UMMS begins MBL-HCV1 Phase 2 trial to prevent hepatitis C virus infection in liver transplant patients

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.